Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

COLLIN M BLAKELY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1528287174
CMS profile
776938
Location
SAN FRANCISCO, CA

General Payments · PY2018–2024

$75,449.25

  • Reported across 58 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$11,469.02

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
TAIHO ONCOLOGY, INC. $5,485.34 7
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 1
Janssen Scientific Affairs, LLC $1,875.00 1
E.R. Squibb & Sons, L.L.C. $650.00 1
Genentech, Inc. $625.00 1
PFIZER INC. $133.68 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $1,266.02 10
PY2019 $5,512.02 16
PY2020 $10,639.75 9
PY2021 $560.00 1
PY2022 $22,377.50 3
PY2023 $23,624.94 7
PY2024 $11,469.02 12

Payment records · PY2024 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
E.R. Squibb & Sons, L.L.C. $650.00 01/11/2024 Consulting Fee Undisputed 01/23/2026 1101371794 CMS
Genentech, Inc. $625.00 02/13/2024 Consulting Fee Undisputed 01/23/2026 1132991537 CMS
Janssen Scientific Affairs, LLC $1,875.00 08/02/2024 Consulting Fee Undisputed 01/23/2026 1078845773 CMS
PFIZER INC. $133.68 02/22/2024 Food and Beverage Undisputed 01/23/2026 1131587927 CMS
TAIHO ONCOLOGY, INC. $693.95 08/15/2024 Travel and Lodging Undisputed 01/23/2026 1137941174 CMS
TAIHO ONCOLOGY, INC. $3,000.00 09/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1137934395 CMS
TAIHO ONCOLOGY, INC. $128.79 09/30/2024 Travel and Lodging Undisputed 01/23/2026 1137936591 CMS
TAIHO ONCOLOGY, INC. $144.10 09/30/2024 Food and Beverage Undisputed 01/23/2026 1137943301 CMS
TAIHO ONCOLOGY, INC. $66.60 10/31/2024 Travel and Lodging Undisputed 01/23/2026 1137937369 CMS
TAIHO ONCOLOGY, INC. $1,200.00 10/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1137937371 CMS
TAIHO ONCOLOGY, INC. $251.90 10/31/2024 Travel and Lodging Undisputed 01/23/2026 1137941176 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 04/02/2024 Consulting Fee Undisputed 01/23/2026 1144953879 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.